1344 related articles for article (PubMed ID: 25641260)
21. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
22. Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes.
Russell-Jones D; Dauchy A; Delgado E; Dimitriadis G; Frandsen HA; Popescu L; Schultes B; Strojek K; Bonnemaire M; Roborel de Climens A; Davies M
Diabetes Obes Metab; 2019 Jul; 21(7):1615-1624. PubMed ID: 30851006
[TBL] [Abstract][Full Text] [Related]
23. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
Yale JF; Pettus JH; Brito-Sanfiel M; Lavalle-Gonzalez F; Merino-Trigo A; Stella P; Chevalier S; Buzzetti R
PLoS One; 2018; 13(1):e0190579. PubMed ID: 29370218
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
26. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.
Dailey G; Lavernia F
Diabetes Obes Metab; 2015 Dec; 17(12):1107-14. PubMed ID: 26139151
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
Oriot P; Jérémie W; Buysschaert M
Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
[TBL] [Abstract][Full Text] [Related]
28. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
Riddle MC; Bolli GB; Home PD; Bergenstal RM; Ziemen M; Muehlen-Bartmer I; Wardecki M; Vinet L; Jeandidier N; Yki-Järvinen H
Diabetes Technol Ther; 2016 Apr; 18(4):252-7. PubMed ID: 26840338
[TBL] [Abstract][Full Text] [Related]
30. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial.
Pan Q; Li Y; Wan H; Wang J; Xu B; Wang G; Jiang C; Liang L; Feng W; Liu J; Wang T; Zhang X; Cui N; Mu Y; Guo L;
Diabetes Obes Metab; 2022 Oct; 24(10):1957-1966. PubMed ID: 35642463
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
Danne T; Tamborlane WV; Malievsky OA; Franco DR; Kawamura T; Demissie M; Niemoeller E; Goyeau H; Wardecki M; Battelino T
Diabetes Care; 2020 Jul; 43(7):1512-1519. PubMed ID: 32430458
[TBL] [Abstract][Full Text] [Related]
34. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).
Matsuhisa M; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Res Clin Pract; 2016 Dec; 122():133-140. PubMed ID: 27835765
[TBL] [Abstract][Full Text] [Related]
35. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
36. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
Danne T; Matsuhisa M; Sussebach C; Goyeau H; Lauand F; Niemoeller E; Bolli GB
Diabetes Obes Metab; 2020 Oct; 22(10):1880-1885. PubMed ID: 32515543
[TBL] [Abstract][Full Text] [Related]
37. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
38. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Meneghini LF; Sullivan SD; Oster G; Busch R; Cali AMG; Dauchy A; Gill J; Bailey TS
Diabetes Obes Metab; 2020 Nov; 22(11):2004-2012. PubMed ID: 32729217
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial.
Ji L; Kang ES; Dong X; Li L; Yuan G; Shang S; Niemoeller E;
Diabetes Obes Metab; 2020 Apr; 22(4):612-621. PubMed ID: 31797549
[TBL] [Abstract][Full Text] [Related]
40. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
